All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Visual abstract | Real-world treatment patterns in third line therapies for RRMM across Europe
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 2
What is the most common class of drug used for third-line therapy to treat relapsed/refractory multiple myeloma across Germany, Italy, Spain, the UK, and France?
A
B
C
D
The Multiple Myeloma Hub is pleased to present a visual abstract representing data from a retrospective multi-country study evaluating treatment patterns in patients with relapsed/ refractory multiple myeloma (RRMM) initiating third-line therapies. Data were collected from patients in Germany, France, Italy, Spain, and the United Kingdom (UK).
The most common third-line treatments by country were recorded by class and agent, as well as comparisons made between historical (2016–2018) and more recent (2019–2021) treatment regimens. The trends identified between countries suggest that physician’s choice of treatment for RRMM varies significantly; however, there is a trend toward triplet regimens in the latest recorded data.1
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?
